Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019

Karlowsky, James A.; Lob, Sibylle; DeRyke, C Andrew; Siddiqui, Fakhar; Young, Katherine; Motyl, Mary; Sahm, Daniel F.

doi:10.1016/j.ijantimicag.2022.106535

Cited by 35 publications

(29 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the ESBL E. coli had shown 100% resistance to cefotaxime and ceftazidime, similarly, the study was conducted by Al-Agamy et al and Kabrah found 100% resistance to the same drugs by the ESBL E. coli [36,37]. High -medium resistance rates (97.5% -46.5%) were detected to 11 resistance to the same drugs in their studies [38][39][40][41][42]. Lower resistance rate to gentamycin (14.7%), tobramycin (12.7%), least resistance to cefoxitin (7.6%) and 100% sensitivity to 8 different antibiotics which are mentioned in Table 4.…”

Section: Discussionsupporting

confidence: 82%

“…The ESBL K. pneumoniae were 100% resistant to ampicillin, aztreonam, cefazolin, cefepime and cefuroxime. Multiples studies from different GCC region including UAE reported the pattern of sensitivity to the same drugs [40,42,[45][46][47]. Higher resistance rate (89%) was identified on cefotaxime and amoxicillin+clavulanate and this was like the study from Bahrain [38], but lower -medium resistance rate was observed to the above drugs in various studies conducted in Kuwait, UAE, Qatar and Saudi Arabia [37,43,47,48].…”

Section: Discussionmentioning

confidence: 76%

“…High - medium resistance rates (97.5% - 46.5%) were detected to 11 different antibiotics. The authors Kasim OA (2019), Shaaban et al (2021) & Mohammed et al (2022) from Bahrain, Alfaresi et al (2018) & Karlowsky et al (2022) from UAE were found that high-medium resistance to the same drugs in their studies [38–42]. Lower resistance rate to gentamycin (14.7%), tobramycin (12.7%), least resistance to cefoxitin (7.6%) and 100% sensitivity to 8 different antibiotics which are mentioned in Table 4 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of class A ESBL, class B and D carbapenemase encoding genes (CTX-M, TEM, SHV, NDM, IMP, OXA-48) in gram-negative bacterial pathogens isolated from various clinical samples collected from northern region of United Arab Emirates

Ragupathi,

Khamisani,

Sadiq

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective The aim of this study was to assess the prevalence of class A ESBL, class B and D carbapenemase encoding genes (blaCTX-M, blaTEM, blaSHV, blaNDM, blaIMP and blaOXA-48) in gram-negative bacterial pathogens isolated from various clinical samples collected from northern region of UAE. Methods A laboratory based experimental study was conducted from October 14, 2021, to June 30, 2022. A total of 3670 various clinical samples (urine, blood, pus, and sputum) were obtained from patients attending the in and out-patient departments of Thumbay University Hospital and various other hospitals of Northern Emirates of UAE, processed for routine bacterial culture examination and determined their antibiotic sensitivity pattern especially ESBL and carbapenem resistance using MicroScan Neg Breakpoint Combo 50 panel. Molecular detection of class A ESBL, class B and D carbapenemase encoding genes (blacTX-M, blaTEM, blaSHV blaNDM, blaIMP & blaOXA-48) were performed on the ESBL and carbapenemase producing gram negative bacteria. Partial genomic sequencing and phylogenetic tree analysis was performed on the most predominant ESBL gene blaCTX-M. Results In total, 1098 bacterial cultures were obtained, of which 833 were gram negative bacteria and among them, 209 (25.1%) were ESBL producers and 40 (4.8%) were both ESBL and carbapenemase producers. In all the 249 bacterial isolates, the ESBL and carbapenemase encoding genes (blaCTX-M, blaTEM, blaSHV, blaNDM & blaIMP) were detected except blaOXA-48. The blaCTX-M (n=72) was the predominantly harbored gene followed by blaTEM (n=56) and blaSHV (n=29), mostly detected in E. coli (n=157), then K. pneumoniae (n=41), P. aeruginosa (n=18) & A. baumannii (n=7). The blaNDM & blaIMP were detected in K. pneumoniae (n=4), A. baumannii (n=3) and P. aeruginosa (n=2) for blaIMP. The gene combinations such as blaCTX-M+TEM (n=15), blaCTX-M+SHV (n=15), blaCTX-M+TEM+SHV (n=6) were co-harbored in 36 E. coli and in the K. pneumoniae, the blaCTX-M+TEM (n=15), blaCTX-M+SHV (n=15), blaTEM+SHV (n=3), blaTEM+NDM (n=1) were detected. The blaCTX-M+TEM, blaCTX-M+SHV & blaCTX-M+TEM+SHV+IMP were detected in one P. aeruginosa and in one A. baumannii, the blaTEM+NDM, blaTEM+IMP & blaCTX-M+TEM+SHV+IMP were detected. Conclusion The highest bacterial culture positivity was detected in the urine samples. 25.1% of the Gram-ve bacteria were only ESBL producers and 4.8% were both the ESBL & carbapenemase producers. 44.5% of ESBL & carbapenemase producing bacteria harbored the blaCTX-M and mostly detected in the E. coli, then K. pneumoniae and P. mirabilis. Multiple gene combinations were detected in 5% P. aeruginosa, 10% A. baumannii and 3.82% E. coli. This finding highlights the importance of molecular detection of ESBL & carbapenemase producing genes to emphasize the monitor and control the development of multi drug resistant Gram-ve bacterial pathogens.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of class A ESBL, class B and D carbapenemase encoding genes (CTX-M, TEM, SHV, NDM, IMP, OXA-48) in gram-negative bacterial pathogens isolated from various clinical samples collected from northern region of United Arab Emirates

Ragupathi,

Khamisani,

Sadiq

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…These infections lead to poor outcomes in critically ill patients. [32][33][34][35] Several models predicting MDRO infection have been developed, 18-21 36 37 potentially supporting infection control and prevention measures. To the best of our knowledge, one systematic review has evaluated the evidence on models predicting ESBL colonisation or infection.…”

Section: Discussionmentioning

confidence: 99%

“…The rates of infections caused by MDROs (eg, MRSA, CRE, VRE and ESBL-EKP) are increasing. These infections lead to poor outcomes in critically ill patients 32–35. Several models predicting MDRO infection have been developed,18–21 36 37 potentially supporting infection control and prevention measures.…”

Section: Discussionmentioning

confidence: 99%

Clinical prediction models for multidrug-resistant organism colonisation or infection in critically ill patients: a systematic review protocol

et al. 2022

View full text Add to dashboard Cite

IntroductionMultidrug-resistant organisms (MDROs) are pathogenic bacteria that are the leading cause of hospital-acquired infection which is associated with high morbidity and mortality rates in intensive care units, increasing hospitalisation duration and cost. Predicting the risk of MDRO colonisation or infection for critically ill patients supports clinical decision-making. Several models predicting MDRO colonisation or infection have been developed; however, owing to different disease scenarios, bacterial species and few externally validated cohorts in different prediction models; the stability and applicability of these models for MDRO colonisation or infection in critically ill patients are controversial. In addition, there are currently no standardised risk scoring systems to predict MDRO colonisation or infection in critically ill patients. The aim of this systematic review is to summarise and assess models predicting MDRO colonisation or infection in critically ill patients and to compare their predictive performance.Methods and analysisWe will perform a systematic search of PubMed, Cochrane Library, CINAHL, Embase, Web of science, China National Knowledge Infrastructure and Wanfang databases to identify all studies describing the development and/or external validation of models predicting MDRO colonisation or infection in critically ill patients. Two reviewers will independently extract and review the data using the Data Extraction for Systematic Reviews of Prediction Modelling Studies checklist; they will also assess the risk of bias using the Prediction Model Risk of Bias Assessment Tool. Quantitative data on model predictive performance will be synthesised in meta-analyses, as applicable.Ethics and disseminationEthical permissions will not be required because all data will be extracted from published studies. We intend to publish our results in peer-reviewed scientific journals and to present them at international conferences on critical care.PROSPERO registration numberCRD42022274175.

show abstract

Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms

Koenig,

Kuti

2024

Pharmacotherapy

View full text Add to dashboard Cite

Antibiotic resistance has become a global threat as it is continuously growing due to the evolution of β‐lactamases diminishing the activity of classic β‐lactam (BL) antibiotics. Recent antibiotic discovery and development efforts have led to the availability of β‐lactamase inhibitors (BLIs) with activity against extended‐spectrum β‐lactamases as well as Klebsiella pneumoniae carbapenemase (KPC)‐producing carbapenem‐resistant organisms (CRO). Nevertheless, there is still a lack of drugs that target metallo‐β‐lactamases (MBL), which hydrolyze carbapenems efficiently, and oxacillinases (OXA) often present in carbapenem‐resistant Acinetobacter baumannii. This review aims to provide a snapshot of microbiology, pharmacology, and clinical data for currently available BL/BLI treatment options as well as agents in late stage development for CRO harboring various β‐lactamases including MBL and OXA‐enzymes.

show abstract

Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019

Cited by 35 publications

References 15 publications

Prevalence of class A ESBL, class B and D carbapenemase encoding genes (CTX-M, TEM, SHV, NDM, IMP, OXA-48) in gram-negative bacterial pathogens isolated from various clinical samples collected from northern region of United Arab Emirates

Prevalence of class A ESBL, class B and D carbapenemase encoding genes (CTX-M, TEM, SHV, NDM, IMP, OXA-48) in gram-negative bacterial pathogens isolated from various clinical samples collected from northern region of United Arab Emirates

Clinical prediction models for multidrug-resistant organism colonisation or infection in critically ill patients: a systematic review protocol

Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms

Contact Info

Product

Resources

About